EBI3 (IL-27 subunit) Mouse anti-Human, PE, Clone: ebic6, eBioscience™
Mouse Monoclonal Antibody
Brand: Affymetrix eBioscience 12-7358-42
Additional Details : Weight : 0.23750kg
DescriptionIL-35 has been found to suppress the proliferation and function of effector T cells, and has also been observed to induce a regulatory phenotype on naive CD4+ cells cultured in its presence. ELISA results from the culture of human dendritic cells stimulated shown above suggests that at least some of the EBI3 detected by flow is dimerized with p28 to form IL-27. Testing with ebic6 in the context of IL-35 is currently in process. For more information, please contact technical support. Applications Reported: This ebic6 antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This ebic6 antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis using the Intracellular Fixation & Permeabilization Buffer Set (cat. 88-8824) and protocol. Please refer to Best Protocols: Protocol A: Two step protocol for (cytoplasmic) intracellular proteins located under the Resources Tab online. This antibody can be used at 5 µL (0.03 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered. EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35 (1-3). Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naive but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.
|EBI3 (IL-27 subunit)|
|PBS with 0.1% gelatin, 0.2% BSA and 0.09% sodium azide; pH 7.2|
|IL-27B, IL27B; EBV-induced gene 3 protein; Epstein-Barr virus induced gene 3; IL-27 subunit beta; IL27 subunit; IL35 subunit; cytokine receptor; epstein-Barr virus-induced gene 3 protein; interleukin-27 subunit beta|
|4° C, store in dark, DO NOT FREEZE!|
For Research Use Only.